Abstract:BACKGROUND & OBJECTIVE:Docetaxel and cisplatin (DDP) are effective drugs for head and neck tumors. Stage II-III clinical trial of TP regimen (docetaxel combined DDP) for head and neck tumors has completed. This study was to compare the efficacy and toxicity of TP regimen and PF regimen [DDP combined 5-fluorouracil (5-FU)] in treating nasopharyngeal carcinoma (NPC), to provide a new chemotherapeutic regimen for NPC. METHODS:Twenty NPC patients treated in Cancer Center of Sun Yat-sen University between Oct. 1, 2005 and Mar. 1, 2006 were subjected to study group (TP group). Twenty patients were chosen randomly from the 45 NPC patients treated with PF regimen between May 1, 2004 and Sep. 30, 2005 as control group (PF group). Both groups received concurrent radiotherapy. The efficacy and adverse events of the 2 groups were compared. RESULTS:The mean number of chemotherapy cycles was significantly higher in TP group than in PF group (3.85 cycles vs. 2.75 cycles, P<0.001). After induction chemotherapy, in TP group, 18 achieved partial remission (PR) and 2 had stable disease (SD) for nasopharyngeal lesions, 7 achieved complete remission (CR), 11 achieved PR and 2 had SD for regional lymph nodes; in PF group, 17 achieved PR and 3 had SD for nasopharyngeal lesions, 2 achieved CR, 15 achieved PR and 1 had SD for regional lymph nodes. After concurrent chemoradiotherapy, all in TP group and 18 in PF group achieved CR for nasopharyngeal lesions, and 19 in TP group and 15 in PF group achieved CR for regional lymph nodes. There was no significant difference in efficacy between the 2 groups (P>0.05). The occurrence rates of grade 3-4 neutropenia were significantly higher in TP group than in PF group (40.5% vs. 0% after induction chemotherapy, 40.5% vs. 10.2% after concurrent radiochemotherapy, P<0.05). The occurrence rates of anemia and thrombocytopenia were significantly lower in TP group than in PF group (P<0.05). The uses of antibiotics and parenteral nutritional support in the 2 groups were similar. CONCLUSION:The efficacy of TP regimen on NPC is similar to that of PF regimen, and the adverse events are tolerable, but the long-term outcomes and toxicities need to be further investigated.

Comparison of NP Regimen and TP Regimen in Treatment of Advanced Breast Cancer

Clinical Study of Paclitaxel Plus Cisplatin Versus Vinorelbine Plus Cisplatin in Treatment of Patients with Advanced Non-Small-cell Lung Cancer

A Clinical Study on Efficacy and Toxicity of NP in Contrast to the MNP Combination Chemotherapy in Patients with Advanced Non-small Cell Lung Cancer

Comparison of Cisplatin-Mitomycin-vinorelbine Versus Cisplatin-Mitomycin-vindesine Regimen for Treatment of Advanced Non-Small Cell Lung Cancer: a Report of 83 Patients

Chemotherapy of NA and NP regimens in 48 patients with advanced breast cancer

[A Randomized Comparative Trial of Three Combined Regimens Containing Cisplatin for Treatment of Advanced Non-Small Cell Lung Cancer].

A systematic review in paclitaxel plus platinum versus vinorelbine plus cisplatin for advanced non small cell lungcancer

Comparison of Vinorelbine Plus Cisplatin with Vinorelbine Plus Capecitabine in Patients with Anthracyclines- and Taxanes-Refractory Advanced Breast Cancer*

Comparison of Different Regimen in Treatment of Patients with Advanced Non-Small Cell Lung Cancer

[Comparison of Cisplatin Combined with Gemcitabine Versus Cisplatin Combined with Vinorelbine Regimen for Treatment of Patients with Advanced Non-Small Cell Lung Cancer].

A Comparative Study for Vinorelbine with Cisplatin Plus Mitomycin and Vinorelbine with Cisplatin in Advanced Non-Small-cell Lung Cancer

Comparison of Short-term Efficacy between the NP and GP Regimens in the Treatment of Advanced Non-small-cell Lung Canaer

The Efficacy Compares of Platinum Regimen Chemotherapy among 60 Treat-naive Advanced Nonsmall Cell Lung Carcinoma Patients

Randomized trial of gemcitabine plus cisplatin versus paclitaxel plus cisplatin in treating advanced non-small cell lung cancer

[Efficacy and Toxicity of Vinorelbine (Nvb)-Based Regimens in Patients with Metastatic Triple Negative Breast Cancer (mtnbc) Pretreated with Anthracyclines and Taxanes].

Retrospective comparisons of nanoparticle albumin-bound paclitaxel and docetaxel neoadjuvant regimens for breast cancer

First-line regimen of Vinorelbine and Cisplatin(NP) combined with cyclooxygenase-2 inhibitor celecoxib in advanced non-small-cell lung cancer

A Randomized Comparative Trial of TP and GP Regimen for Treatment of Advanced Non-Small Cell Lung Cancer

[Comparison of Efficacy of Docetaxel Combined Cisplatin (TP Regimen) and Cisplatin Combined 5-Fluorouracil (PF Regimen) on Locally Advanced Nasopharyngeal Carcinoma].

[Effects and Toxicity of Neoadjuvant Chemotherapy with Vinorelbine and Cisplatin in Treatment of Operable Breast Cancer Previously Non-Responsive to Anthracyclines and Taxanes-Containing Regimen: Analysis of 19 Cases].

Vinorelbine plus cisplatin in the treatment of 48 cases with advanced non-small-cell lung cancer